Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Glaucoma: Overview01:25

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
Accessory Structures of the Eye01:17

Accessory Structures of the Eye

Optical perception, or vision, is an extraordinary sense dependent on converting light signals received via the ocular organs. These organs, known as eyes, are securely positioned within the bony cavities of the skull, called orbits. The orbits serve a dual purpose: a protective shield for the ocular globes and a stable attachment point for the soft ocular tissues. The eye's external protective mechanisms include the eyelids, which are edged with lashes that act as a barrier against foreign...
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
Microbiome of the Eye01:22

Microbiome of the Eye

The human eye has a specialized microbiota that reflects its unique anatomical and immunological environment. This low-biomass microbial community predominantly colonizes the conjunctiva and eyelid margins, playing a vital role in ocular surface homeostasis and defense. Despite its proximity to the richly colonized facial skin, the ocular surface maintains a distinct microbial profile due to continuous mechanical and biochemical defense mechanisms.The conjunctival surface hosts fewer microbial...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Impact of an Ophthalmic Cooling Device on Corneal Immune and Sensory Nerve Features in Chronic Ocular Surface Pain: A Prospective, Feasibility Study.

Ophthalmology and therapy·2026
Same author

Should Chronic Ocular Surface Pain (COSP) Be Considered the 11th Chronic Overlapping Pain Condition (COPC)?

American journal of ophthalmology·2026
Same author

Ocular Symptoms After Refractive Surgery.

JAMA ophthalmology·2026
Same author

Which features best differentiate Sjögren's-related from non-Sjögren's-related dry eye disease?

Graefe's archive for clinical and experimental ophthalmology = Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie·2026
Same author

Corneal nerve alterations in migraine: a systematic review of in vivo confocal microscopy and esthesiometry findings.

Contact lens & anterior eye : the journal of the British Contact Lens Association·2026
Same author

Standardized Classification System for Dysphotopsia Reporting.

Ophthalmology. Glaucoma·2026

Related Experiment Video

Updated: May 12, 2026

Development of an In Vitro Ocular Platform to Test Contact Lenses
08:28

Development of an In Vitro Ocular Platform to Test Contact Lenses

Published on: April 6, 2016

10.6K

Preservatives and ocular surface disease: A review.

Malik Y Kahook1, Christopher J Rapuano2, Elisabeth M Messmer3

  • 1Department of Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado School of Medicine, Aurora, CO, United States.

The Ocular Surface
|August 4, 2024
PubMed
Summary

Benzalkonium chloride (BAK) in glaucoma eye drops damages the ocular surface, worsening OSD and impacting surgery success. Reducing BAK exposure through preservative-free options or alternatives is crucial for patient quality of life.

Keywords:
Antihypertensive agents/therapeutic useBenzalkonium chlorideBenzalkonium compounds/adverse effectsDry eye diseaseGlaucoma/drug therapyOcular hypertensionOcular surface diseasePharmaceutical/adverse effectsPreservative-induced ocular surface diseasePreservativesTopical medications

More Related Videos

Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
06:29

Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation

Published on: May 2, 2020

3.8K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

138

Related Experiment Videos

Last Updated: May 12, 2026

Development of an In Vitro Ocular Platform to Test Contact Lenses
08:28

Development of an In Vitro Ocular Platform to Test Contact Lenses

Published on: April 6, 2016

10.6K
Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation
06:29

Effect of Artificial Tear Formulations on the Metabolic Activity of Human Corneal Epithelial Cells after Exposure to Desiccation

Published on: May 2, 2020

3.8K
Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats
06:30

Ocular Therapeutic Delivery and Advanced Tissue Retrieval in Adult Rats

Published on: May 23, 2025

138

Area of Science:

  • Ophthalmology
  • Ocular Surface Disease
  • Glaucoma Management

Background:

  • Iatrogenic ocular surface disease (OSD) is common in glaucoma patients using preserved topical antihypertensive drugs.
  • Benzalkonium chloride (BAK) preservatives damage ocular surface structures and activate inflammation.
  • Chronic BAK exposure negatively impacts glaucoma treatment outcomes and surgical success.

Purpose of the Study:

  • To review the detrimental effects of BAK on the ocular surface.
  • To explore strategies for minimizing or eliminating BAK exposure in glaucoma patients.
  • To improve patient quality of life and prevent complications from chronic BAK exposure.

Main Methods:

  • Literature review of studies on BAK effects and preservative strategies.
  • Analysis of ocular surface damage mechanisms induced by BAK.
  • Evaluation of alternative preservatives and preservative-free formulations.

Main Results:

  • BAK causes significant damage to the ocular surface barrier, corneal cells, nerves, and goblet cells.
  • Inflammatory pathways activated by BAK can compromise glaucoma surgery.
  • Reducing BAK exposure is essential for managing OSD and improving treatment efficacy.

Conclusions:

  • Minimizing BAK exposure is key to managing iatrogenic OSD in glaucoma patients.
  • Preservative-free formulations are the preferred strategy, with alternatives considered cautiously.
  • Non-pharmacological interventions may also be beneficial for ocular surface health.